Immuneering (IMRX) Competitors $6.50 +0.39 (+6.38%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$6.65 +0.15 (+2.31%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. ARDX, STOK, XERS, ZYME, AMLX, SION, TLRY, PHVS, AMPH, and EVOShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Ardelyx (ARDX), Stoke Therapeutics (STOK), Xeris Biopharma (XERS), Zymeworks (ZYME), Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), Tilray Brands (TLRY), Pharvaris (PHVS), Amphastar Pharmaceuticals (AMPH), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Its Competitors Ardelyx Stoke Therapeutics Xeris Biopharma Zymeworks Amylyx Pharmaceuticals Sionna Therapeutics Tilray Brands Pharvaris Amphastar Pharmaceuticals Evotec Ardelyx (NASDAQ:ARDX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability. Which has preferable earnings and valuation, ARDX or IMRX? Ardelyx has higher revenue and earnings than Immuneering. Ardelyx is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.61M3.66-$39.14M-$0.23-22.00ImmuneeringN/AN/A-$61.04M-$1.89-3.44 Do analysts rate ARDX or IMRX? Ardelyx currently has a consensus target price of $11.70, indicating a potential upside of 131.23%. Immuneering has a consensus target price of $16.40, indicating a potential upside of 152.31%. Given Immuneering's higher probable upside, analysts plainly believe Immuneering is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91Immuneering 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43 Does the media favor ARDX or IMRX? In the previous week, Immuneering had 2 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Ardelyx. Immuneering's average media sentiment score of 1.33 beat Ardelyx's score of 0.65 indicating that Immuneering is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ARDX or IMRX? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 4.8% of Ardelyx shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, ARDX or IMRX? Ardelyx has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Is ARDX or IMRX more profitable? Immuneering has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Ardelyx's return on equity of -36.57% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-14.60% -36.57% -13.42% Immuneering N/A -146.28%-117.22% SummaryArdelyx beats Immuneering on 9 of the 16 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.99M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-3.4421.5785.4827.61Price / SalesN/A271.42535.60201.12Price / CashN/A47.1237.9261.55Price / Book4.8910.1412.976.76Net Income-$61.04M-$52.31M$3.30B$275.88M7 Day Performance-0.46%5.14%4.35%2.81%1 Month Performance-7.80%14.68%9.50%9.24%1 Year Performance196.80%30.98%84.38%35.42% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.9142 of 5 stars$6.50+6.4%$16.40+152.3%+172.0%$253.99MN/A-3.4460Positive NewsAnalyst ForecastShort Interest ↑Gap UpARDXArdelyx4.3134 of 5 stars$5.63+1.6%$11.70+107.8%-15.1%$1.34B$333.61M-24.4890News CoverageAnalyst ForecastSTOKStoke Therapeutics3.2472 of 5 stars$24.73+2.4%$25.57+3.4%+148.4%$1.32B$36.56M29.09100News CoverageAnalyst ForecastInsider TradeXERSXeris Biopharma2.8577 of 5 stars$8.08-1.2%$7.08-12.3%+178.9%$1.32B$203.07M-38.47290News CoverageAnalyst ForecastZYMEZymeworks2.0903 of 5 stars$17.23+3.8%$21.43+24.4%+33.1%$1.30B$122.87M-11.49460News CoveragePositive NewsAnalyst RevisionAMLXAmylyx Pharmaceuticals2.1596 of 5 stars$14.90+2.6%$14.50-2.7%+313.5%$1.29B-$249K-5.96200Analyst ForecastSIONSionna Therapeutics2.79 of 5 stars$29.52+2.0%$38.00+28.7%N/A$1.28BN/A0.0035Analyst ForecastInsider TradeTLRYTilray Brands2.0573 of 5 stars$1.85+60.9%$1.94+4.7%+4.2%$1.27B$821.31M-0.802,842Trending NewsAnalyst ForecastHigh Trading VolumePHVSPharvaris2.2198 of 5 stars$24.26+0.4%$34.00+40.1%+28.4%$1.26BN/A-7.2230News CoveragePositive NewsAnalyst ForecastAMPHAmphastar Pharmaceuticals4.5035 of 5 stars$26.92+0.3%$31.60+17.4%-43.9%$1.25B$731.97M10.082,028Positive NewsAnalyst ForecastEVOEvotec1.6079 of 5 stars$3.54+1.7%$5.40+52.5%+22.1%$1.24B$862.40M0.004,827News CoverageAnalyst Forecast Related Companies and Tools Related Companies ARDX Alternatives STOK Alternatives XERS Alternatives ZYME Alternatives AMLX Alternatives SION Alternatives TLRY Alternatives PHVS Alternatives AMPH Alternatives EVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
